EUVIMEDEUVIMED entdecken
CrossrefInfokarte

OPTIMIZATION OF THE CLINICAL JOURNEY OF UNFIT PATIENTS WITH NEWLY DIAGNOSED IDH1M ACUTE MYELOID LEUKEMIA

Adriano Venditti, Marta Riva, Livio Pagano, Giovanni Marconi, Nicola Fracchiolla, Romano Danesi, Antonio Curti, Anna Candoni, Erika Borlenghi, Maria Teresa Voso

Mediterranean Journal of Hematology and Infectious Diseases · 2026-10-31 · 18 (1) · e2026086

DOI: 10.4084/mjhid.2026.086 ↗
AbstractBibliografische Angaben

Abstract

The management of acute myeloid leukemia (AML) in elderly or unfit patients has undergone a paradigm shift with the integration of molecular diagnostics and targeted therapies. Among actionable alterations, IDH1 mutations define a biologically distinct subgroup for which ivosidenib combined with azacitidine has recently emerged as a standard of care. However, initial clinical management remains complex. Three main themes emerged from the expert panel’s discussion: all patients should be tested for IDH1m, with turnaround time of 3-5 days; adequate patient monitoring during treatment is essential to detect the earliest signs of differentiation syndrome and QTc prolongation; appropriate management of concomitant therapies is required, not only for azole derivatives administered for antifungal prophylaxis, where need. This paper provides a comprehensive and evidence-based framework for optimizing early management in unfit patients with newly diagnosed IDH1-mutated AML, integrating data from randomized trials, real-world studies, and updated evidence on antifungal prophylaxis and drug–drug interactions in the era of targeted therapies.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →